ClinicalTrials.gg
CompletedNCT03043560Updated Oct 23, 2020Results posted

Study to Treat Major Depressive Disorder With a New Medication

A Phase 2 interventional study of Ezogabine and Placebos in Depressive Disorder and Anhedonia, sponsored by James Murrough. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-10-23.

Sponsored by James Murrough · Phase 2, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 319 studies in Depressive Disorder with a site in United States — 38 open to participants now, 44 under way, 2 of them phase 3. Depressive Disorder · United States.

Enrollment
182nd of 275
45 · median 85
Started
2017
with 16 others
Phase 2
49 of 319
8 open now
Registered
174th of 319
by date

Among the 319 studies in Depressive Disorder with a site in United States, this one is the 182nd largest by enrollment of the 275 interventional ones that give a count, is one of 17 that started in 2017, is one of 49 in phase 2, and was the 174th registered.

Depressive Disorder

857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.

Browse Depressive Disorder studies →

Open to participants now

38 of the 319 studies in Depressive Disorder with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 319 studies in Depressive Disorder with a site in United States, or all of them as a file.
02

Study summary

This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener ezogabine (Potiga, GlaxoSmithKline; FDA-approved for the treatment of seizure disorders).

Read the detailed description

Depressive disorders are among the most disabling medical conditions worldwide and currently available treatments fall short of addressing this large public health burden. Dysfunction within the brain reward system is emerging as a core feature of depressive disorders, in particular related to deficits in motivation, interest, and response to pleasure (e.g., anhedonia: markedly diminished response to pleasure). Evidences from a series of preclinical studies from our group highlighted the KCNQ subtype of neuronal potassium (K+) channel as a novel target for the treatment of depressive disorders and our human pilot study showed a reduction in anhedonia and related symptoms, and an increased brain response to reward (as measured by functional magnetic resonance imaging [fMRI]) following treatment with ezogabine. Building on this data, the current project will assess reward circuit activity following treatment with ezogabine in depressed patients with a current depressive disorder (Major depressive disorder [MDD], persistent depressive disorder, other specified depressive disorder) and anhedonia (defined by a score ≥ 20 on the Snaith-Hamilton Pleasure Scale [SHAPS]), using fMRI to investigate the cortico-striatal circuit to reward.

This study represents the first part of the R61/R33 National Institutes of Health (NIH) founded project. A clear increase in reward circuit activation in at least one ezogabine treatment group compared to placebo, given acceptable tolerability, will constitute a "go" and the project will move to the next phase (R33), where we aim to examine the relationship between treatment, reward circuit activity, and behavioral and clinical outcomes in a larger, confirmatory efficacy trial of ezogabine for depression with anhedonia.

03

Conditions studied

  • Depressive Disorder
  • Anhedonia

Keywords

  • depression
  • anhedonia
  • reward
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written obtained from subject and ability for subject to comply with the requirements of the study;
  • Men and women, age 18-65;
  • Participants must meet criteria for current depressive disorder (major depressive disorder [MDD], persistent depressive disorder, other specified depressive disorder) as determined by a study psychiatrist and confirmed using the Structured Clinical Interview for DSM-V (SCID);
  • anhedonia as determined by a SHAPS score ≥ 20 at screening;
  • Current illness severity is at least moderate, defined as a score of ≥4 on the Clinical Global Impression-Severity (CGI-S) Scale;
  • If female of , must agree to use of a medically accepted form of , or else agree to abstinence.

Exclusion criteria

Exclusion Criteria:

  • A primary psychiatric diagnosis other than a depressive disorder as defined by [co-morbid anxiety disorders (including agoraphobia, generalized anxiety disorder, social anxiety disorder and panic disorder) and Posttraumatic Stress Disorder (PTSD) are allowed] or major cognitive disorder;
  • Meets criteria for a substance or alcohol use disorder in the past 6 months;
  • Female participants who are pregnant, breastfeeding, or may become pregnant, or unwilling to practice during participation in the study;
  • Positive urine toxicology screen for drugs of abuse at the time of screening;
  • Any unstable medical illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease;
  • abnormalities of laboratory tests, physical examination, or ;
  • Prolonged at screening, operationalized as a QTc of > 480 ms;
  • A history of retinal abnormalities (i.e., pigment changes, retinal dystrophy) or findings of retinal pathology on ophthalmological exam at baseline;
  • Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data;
  • Use of any dis-allowed medication according to the study protocol;
  • Serious and imminent risk of self harm or violence as determined by the PI;
  • Extreme illness severity as defined by a GCI-S score >6;
  • Any to MRI including claustrophobia, any trauma or surgery which may have left magnetic material in the body, magnetic implants or pacemakers, and inability to lie still for 1 hour or more;
  • History of non-response to electroconvulsive therapy in the current depressive episode

    • Exceptions:

      1. Subjects with a positive urine drug screen for cannabinoids, barbiturates, opiates, amphetamines, or benzodiazepines may be allowed in the study provided that the drug was used for a documented, legitimate medical purpose and/or the use of such products may be discontinued (documented by a negative repeat test) prior to randomization;
      2. Medically appropriate episodic use (up to 3 days) of narcotic analgesics for acute medical indications is allowed (Discussion with PI required)

        • Potential participants will not be discontinued from medication for the purposes of this study. If a patient is taking a protocol dis-allowed medication at the time of screening, the patient may discontinue the medication under the supervision of the treating physician in the case that the patient is not benefiting from the medication or otherwise wishes to discontinue the medication. In no case will a dis-allowed medication be discontinued for the purpose of study participation if the patient is receiving clinical benefit from the medication.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Ezogabine

    Participants will receive treatment with ezogabine up to 900mg/day.

    Drug: Ezogabine

  • Placebo comparator
    Placebo

    Participants will receive treatment with a matching placebo pill.

    Drug: Placebos

Interventions

  • daily for 5 weeks

    Also known as: Potiga

  • DrugPlacebos

    placebo pill daily for 5 weeks

06

What researchers measure

Primary outcomes

  1. Change in Ventral Striatum (VS) Activation

    change in activation during reward anticipation within the bilateral VS from baseline (Study Visit 0) to the primary outcome visit (Study Visit 5) as measured by functional MRI during the incentive flanker task (IFT). The IFT, like the Monetary Incentive Delay task, permits discrete modeling of brain activity during anticipation of an incentive. Functional scans were preprocessed and denoised for motion and physiological noise using multi-echo independent component analysis (ME-ICA). Task-based modeling was conducted using AFNI and FSL software. The primary outcome for reward anticipation was the contrast of reward cue compared to neutral cue (reward\>neutral cue). The primary imaging outcome was analyzed using a linear mixed model with a single random intercept term treating time as discrete or continuous as appropriate.

    Time frame: baseline and 5 weeks

Secondary outcomes

  1. Change in Snaith-Hamilton Pleasure Scale (SHAPS)

    The SHAPS is a well-validated 14-item self-report questionnaire commonly used to assess anhedonia. Each item on the SHAPS is worded so that higher scores indicate greater pleasure capacity. A total score can be derived by summing the responses to each item. Items answered with "strongly agree" are coded as "1", while a "strongly disagree" response was assigned a score of "4." Total scores on the SHAPS can range from 14 to 56, with higher scores corresponding to higher levels of anhedonia.

    Time frame: baseline and 5 weeks

  2. Clinical Global Impression - Improvement (CGI-I)

    A widely administered clinician rated global measure of the degree of improvement from the initial assessment in subject overall illness severity. 7 point scale rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.

    Time frame: baseline and 5 weeks

  3. Clinical Global Impression - Severity (CGI-S)

    Clinician rated global measure of subject overall illness severity. a 7-point scale rated as 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.

    Time frame: baseline and 5 weeks

  4. Anticipatory and Consummatory Interpersonal Pleasure Scale (ACIPS)

    A measure specifically designed to assess hedonic capacity for social and interpersonal pleasure.The ACIPS is a 17-item self-report measure scored on a likert scale, ranging from 1 (very false for me) to 6 (very true for me). Full scale from 17-102, higher score indicates higher hedonic capacity

    Time frame: baseline and 5 weeks

  5. Montgomery-Asberg Depression Rating Scale (MADRS)

    A 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Each items is scored 0 (normal) to 6 (severe depression) with overall score ranges from 0 (normal) to 60 (severe depression).

    Time frame: baseline and 5 weeks

  6. World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)

    A 12-item generic assessment instrument that measures the level of functioning. Each item is scored from 0 to 4 and the items are summed to provide a total score. The score therefore ranges from 0 to 48, with higher scores indicating greater disability.

    Time frame: baseline and 5 weeks

  7. Temporal Experience of Pleasure Scale (TEPS)

    The TEPS is composed of 18-items rated on a likert-type scale ranging from 1 (Very True for me) to 6 (Very False for me), and yields two subscales. Ten items make up the TEPS-Anticipatory Pleasure (TEPS-ANT) scale with a range from 10 (not motivated) to 60 (highly motivated). The other eight TEPS items make up the TEPS-Consummatory Pleasure (TEPS-CON) scale; range from 8 (not responsive) to 48 (highly responsive). Total scores range is 18-108. Lower scores indicate greater levels of anhedonia.

    Time frame: baseline and 5 weeks

  8. Specific Loss of Interest and Pleasure Scale (SLIPS)

    The SLIPS is a recently developed and validated measure of anhedonia that is tailored to detect recent changes in anhedonia. A 23-item measure, each item range from 0-3. Full scale from 0 to 69, higher score indicates more recent changes.

    Time frame: baseline 5 weeks

07

Results

Posted Oct 23, 2020
Limitations and caveats
The relatively small sample size and termination of enrollment prior to the planned target limit conclusions regarding efficacy and generalizability.

Participant flow

Participants recruited from Sept 2017 through August 2019

Participant flow — Overall Study
MilestoneEzogabinePlacebo
Started2124
Completed2021
Not completed13
Withdrew: Discontinued intervention12
Withdrew: Lost to follow-up01

Outcome measures

PrimaryChange in Ventral Striatum (VS) Activation

change in activation during reward anticipation within the bilateral VS from baseline (Study Visit 0) to the primary outcome visit (Study Visit 5) as measured by functional MRI during the incentive flanker task (IFT). The IFT, like the Monetary Incentive Delay task, permits discrete modeling of brain activity during anticipation of an incentive. Functional scans were preprocessed and denoised for motion and physiological noise using multi-echo independent component analysis (ME-ICA). Task-based modeling was conducted using AFNI and FSL software. The primary outcome for reward anticipation was the contrast of reward cue compared to neutral cue (reward\>neutral cue). The primary imaging outcome was analyzed using a linear mixed model with a single random intercept term treating time as discrete or continuous as appropriate.

Time frame:
baseline and 5 weeks
Reported as:
Mean · Bold Oxygen-level Dependent (BOLD) Signa
Change in Ventral Striatum (VS) Activation
Bold Oxygen-level Dependent (BOLD) SignaEzogabinePlacebo
baseline-0.26 ± 0.690.95 ± 0.79
5 weeks0.176 ± 0.810.015 ± 0.68
SecondaryChange in Snaith-Hamilton Pleasure Scale (SHAPS)

The SHAPS is a well-validated 14-item self-report questionnaire commonly used to assess anhedonia. Each item on the SHAPS is worded so that higher scores indicate greater pleasure capacity. A total score can be derived by summing the responses to each item. Items answered with "strongly agree" are coded as "1", while a "strongly disagree" response was assigned a score of "4." Total scores on the SHAPS can range from 14 to 56, with higher scores corresponding to higher levels of anhedonia.

Time frame:
baseline and 5 weeks
Reported as:
Mean · score on a scale
Change in Snaith-Hamilton Pleasure Scale (SHAPS)
score on a scaleEzogabinePlacebo
Baseline38.7 ± 8.133.7 ± 6
5 weeks27.5 ± 8.530 ± 10.9
SecondaryClinical Global Impression - Improvement (CGI-I)

A widely administered clinician rated global measure of the degree of improvement from the initial assessment in subject overall illness severity. 7 point scale rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.

Time frame:
baseline and 5 weeks
Reported as:
Mean · score on a scale
Clinical Global Impression - Improvement (CGI-I)
score on a scaleEzogabinePlacebo
baseline4 ± 0.24 ± 0.4
5 weeks2.1 ± 12.8 ± 1.3
SecondaryClinical Global Impression - Severity (CGI-S)

Clinician rated global measure of subject overall illness severity. a 7-point scale rated as 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.

Time frame:
baseline and 5 weeks
Reported as:
Mean · score on a scale
Clinical Global Impression - Severity (CGI-S)
score on a scaleEzogabinePlacebo
baseline4.4 ± 0.54.6 ± 0.6
5 weeks2.6 ± 1.23.3 ± 1.2
SecondaryAnticipatory and Consummatory Interpersonal Pleasure Scale (ACIPS)

A measure specifically designed to assess hedonic capacity for social and interpersonal pleasure.The ACIPS is a 17-item self-report measure scored on a likert scale, ranging from 1 (very false for me) to 6 (very true for me). Full scale from 17-102, higher score indicates higher hedonic capacity

Time frame:
baseline and 5 weeks
Reported as:
Mean · score on a scale
Anticipatory and Consummatory Interpersonal Pleasure Scale (ACIPS)
score on a scaleEzogabinePlacebo
baseline46.1 ± 15.153.7 ± 15
5 weeks65.1 ± 22.859 ± 23.5
SecondaryMontgomery-Asberg Depression Rating Scale (MADRS)

A 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Each items is scored 0 (normal) to 6 (severe depression) with overall score ranges from 0 (normal) to 60 (severe depression).

Time frame:
baseline and 5 weeks
Reported as:
Mean · score on a scale
Montgomery-Asberg Depression Rating Scale (MADRS)
score on a scaleEzogabinePlacebo
baseline28.3 ± 6.126.8 ± 5.1
5 weeks12.7 ± 8.718.5 ± 10.1
SecondaryWorld Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)

A 12-item generic assessment instrument that measures the level of functioning. Each item is scored from 0 to 4 and the items are summed to provide a total score. The score therefore ranges from 0 to 48, with higher scores indicating greater disability.

Time frame:
baseline and 5 weeks
Reported as:
Mean · score on a scale
World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)
score on a scaleEzogabinePlacebo
baseline15.5 ± 7.516.5 ± 9.4
5 weeks10.2 ± 9.511.6 ± 9.8
SecondaryTemporal Experience of Pleasure Scale (TEPS)

The TEPS is composed of 18-items rated on a likert-type scale ranging from 1 (Very True for me) to 6 (Very False for me), and yields two subscales. Ten items make up the TEPS-Anticipatory Pleasure (TEPS-ANT) scale with a range from 10 (not motivated) to 60 (highly motivated). The other eight TEPS items make up the TEPS-Consummatory Pleasure (TEPS-CON) scale; range from 8 (not responsive) to 48 (highly responsive). Total scores range is 18-108. Lower scores indicate greater levels of anhedonia.

Time frame:
baseline and 5 weeks
Reported as:
Mean · score on a scale
Temporal Experience of Pleasure Scale (TEPS)
score on a scaleEzogabinePlacebo
TEPS-ANT baseline26.3 ± 8.328.6 ± 8.7
TEPS-ANT 5 weeks37.3 ± 10.532.4 ± 11.5
TEPS-CON baseline24.8 ± 8.125.6 ± 7.6
TEPS-CON 5 weeks32.2 ± 629.9 ± 10.5
SecondarySpecific Loss of Interest and Pleasure Scale (SLIPS)

The SLIPS is a recently developed and validated measure of anhedonia that is tailored to detect recent changes in anhedonia. A 23-item measure, each item range from 0-3. Full scale from 0 to 69, higher score indicates more recent changes.

Time frame:
baseline 5 weeks
Reported as:
Mean · score on a scale
Specific Loss of Interest and Pleasure Scale (SLIPS)
score on a scaleEzogabinePlacebo
baseline32.3 ± 9.828.8 ± 10.4
5 weeks16.3 ± 16.721.5 ± 16.8

Adverse events

Collected over 8 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ezogabine0/21 (0%)0/21 (0%)21/21 (100%)
Placebo0/24 (0%)0/24 (0%)19/24 (79.2%)
Most frequent other events
Showing 10 of 28
Most frequent other events
EventEzogabinePlacebo
DizzinessNervous system disorders21/215/24
OtherGeneral disorders9/218/24
HeadacheNervous system disorders5/217/24
DiarrheaGastrointestinal disorders5/211/24
NauseaGastrointestinal disorders3/215/24
Confusional statePsychiatric disorders4/210/24
Disturbance in attentionNervous system disorders3/210/24
Vision blurredEye disorders3/211/24
Abdominal PainGastrointestinal disorders2/213/24
SomnolenceNervous system disorders2/213/24

Baseline characteristics

Age, Continuous
Age, Continuous(years)EzogabinePlaceboTotal
Mean44.4 ± 13.638.9 ± 14.341.5 ± 14.1
Sex: Female, Male
Sex: Female, Male(Participants)EzogabinePlaceboTotal
Female101222
Male111223
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)EzogabinePlaceboTotal
White/Caucasian121224
Black/African American5712
Hispanic/Latino6915
Employment at least Part-Time
Employment at least Part-Time(Participants)EzogabinePlaceboTotal
Count of participants91423
Educational Attainment - ast least some college
Educational Attainment - ast least some college(Participants)EzogabinePlaceboTotal
Count of participants152136
Relationship Status - Single, Never Married
Relationship Status - Single, Never Married(Participants)EzogabinePlaceboTotal
Count of participants81321
Primary Diagnosis
Primary Diagnosis(Participants)EzogabinePlaceboTotal
Major Depressive Disorder212344
Persistent Depressive Disorder011
Current Major Depressive Episode
Current Major Depressive Episode(Participants)EzogabinePlaceboTotal
Count of participants212243

4 further baseline measures are reported on the registry.

08

Study locations

2 sites
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Costi S, Morris LS, Kirkwood KA, Hoch M, Corniquel M, Vo-Le B, Iqbal T, Chadha N, Pizzagalli DA, Whitton A, Bevilacqua L, Jha MK, Ursu S, Swann AC, Collins KA, Salas R, Bagiella E, Parides MK, Stern ER, Iosifescu DV, Han MH, Mathew SJ, Murrough JW. Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. Am J Psychiatry. 2021 May 1;178(5):437-446. doi: 10.1176/appi.ajp.2020.20050653. Epub 2021 Mar 3. PubMed 33653118 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this study may be submitted to the National Database for Clinical Research Related to Mental Illness (NDCT). NDCT isa data repository run by the National Institute of Mental Health (NIMH) that allows researchers studying mental illness to collect and share deidentified information with each other. During and after the study, the researchers will send deidentified information about health and behavior and in some cases, genetic information, to NDCT. Other researchers nationwide can then file an application with the NIMH to obtain access to deidentified study data for research purposes.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Aug 2019, 23 months.

Results were first posted in Oct 2020, 1 year 1 month after primary completion.

Of 43 phase 2 interventional studies under Depressive Disorder, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2017
First posted
Feb 6, 2017
StartActual
Sep 25, 2017
Primary completionActual
Aug 30, 2019
CompletionActual
Aug 30, 2019
Results first posted
Oct 23, 2020
Last update
Oct 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03043560
Lead sponsor
James Murrough
Responsible party
James Murrough (Associate Professor, Icahn School of Medicine at Mount Sinai) — Sponsor-investigator
First posted
Feb 6, 2017
Start date
Sep 25, 2017
Primary completion
Aug 30, 2019
Completion
Aug 30, 2019
Results posted
Oct 23, 2020
Last update
Oct 23, 2020

Study contacts

James Murrough, MD, PhD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ezogabine

Start the discussion